Funder
Ministerio de Ciencia e Innovación
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference26 articles.
1. Targeting PI3K in cancer: mechanisms and advances in clinical trials;Yang;Mol. Canc.,2019
2. Yuan, J.; Mehta, P. P.; Yin, M. J.; Sun, S.; Zou, A.; Chen, J.; Rafidi, K.; Feng, Z.; Nickel, J.; Engebretsen, J.; Hallin, J.; Blasina, A.; Zhang, E.; Nguyen, L.; Sun, M.; Vogt, P. K.; McHarg, A.; Cheng, H.; Christensen, J. G.; Kan, J. L.; Bagrodia, S., PF-04691502, A potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol. Canc. Therapeut. 2011, 10 (11), 2189-2199. doi: 10.1158/1535-7163.MCT-11-0185.
3. Targeting the phosphoinositide 3-kinase pathway in cancer;Liu;Nat. Rev. Drug Discov.,2009
4. Growing roles for the mTOR pathway;Sarbassov;Curr. Opin. Cell Biol.,2005
5. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors;Dienstmann;Mol. Canc. Therapeut.,2014
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献